Compare SPDR Gold Trust (GLD) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Gold Trust vs Viatris Inc — how do they compare? SPDR Gold Trust trades at $367.2, while Viatris Inc trades at $17.16 (market cap $19.44B). The key difference: Viatris Inc pays a 2.88% dividend while SPDR Gold Trust pays none, and Viatris Inc is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals.
| GLD | VTRS | |
|---|---|---|
52-Week High | $495.90 | $17.39 |
52-Week Low | $300.96 | $8.74 |
Market Cap | — | $19.44B |
Sector | — | Health |
Enterprise Value | — | $31.65B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLD, tracking physical gold prices, trades at $365.98, down 1.66% amid a bearish technical signal with moving averages indicating selling pressure. Recent U.S. economic data, including jobless claims and inflation figures, influence gold's short-term volatility, while central bank accumulation provides underlying support. The ETF lacks traditional financial ratios as it holds bullion, with performance tied directly to gold market dynamics and macroeconomic factors.
The outlook for GLD hinges on gold's response to Federal Reserve policy and geopolitical tensions, offering a hedge against inflation but facing headwinds from a stronger dollar and rising yields. Risks include interest rate sensitivity and market sentiment shifts, with investors monitoring key resistance near $375 for breakout potential.
Viatris (VTRS) trades at $16.31, down 0.49% on the day, with technical indicators showing a bullish moving average trend despite recent price weakness. The company has beaten earnings expectations for three consecutive quarters, though it reported a significant net loss of -$3.51B in 2025. Analyst consensus leans toward 'Hold' with a $20 price target, representing 22.6% upside potential. Recent positive developments include FDA acceptance of its fast-acting meloxicam NDA and promising Phase 3 results for VR-205 in Japan.
The outlook presents a value recovery opportunity with reasonable valuation metrics (P/S: 1.34, P/B: 1.33) and improving cash flow trends, but significant risks remain including persistent negative profitability margins, high debt levels, and intense generic drug competition. The stock's direction will depend on successful pipeline execution and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
